Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of Triprorelin Acetate in Prostate Cancer
NCT06683066Phase 1Recruiting
- Sponsor
- The Affiliated Hospital of Qingdao University
- Start
- Dec 2024
- Primary completion
- Sep 2025
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of triptorelin in prostate cancer (PCa) (2 arms), sponsored by The Affiliated Hospital of Qingdao University. Primary endpoints: Peak Plasma Concentration at 672 hours, Area under the plasma concentration versus time curve from time 0 to 28 days and 1 more. Started Dec 2024; status: recruiting.
02
Drugs
triptorelin
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT06683066.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06683066.